Israel - English - Ministry of Health

bayer israel ltd - interferon beta 1b - powder and solvent for solution for injection - interferon beta 1b 0.3 mg/vial - interferon beta-1b - interferon beta-1b - use in ambulatory patients with relapsing-remitting multiple sclerosis (rrms) and relapsing progressive m.s. to reduce the frequency of clinical exacerbations. treatment of secondary progressive (sp) form of multiple sclerosis. treatment of patients who have experienced a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, including the prescence of mri abnormalities characteristic of m.s. and if they are determined to be at high risk of developing clinically definite multiple sclerosis.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - interferon beta-1b 0.25mg (20% excess in quantity filled) - injection with diluent - 8 miu - active: interferon beta-1b 0.25mg (20% excess in quantity filled) excipient: albumin hydrochloric acid mannitol sodium hydroxide hydrochloric acid sodium chloride water for injection - betaferon is indicated for: · the treatment of patients with a single clinical event suggestive of multiple sclerosis and at least two clinically silent magnetic resonance imaging (mri) lesions characteristic of multiple sclerosis, if alternative diagnoses have been excluded, · the treatment of ambulatory patients, with relapsing-remitting multiple sclerosis characterised by at least two attacks of neurological dysfunction over a two year period followed by complete or incomplete recovery. · the reduction of frequency and severity of clinical relapses and for slowing the progression of disease in patients with secondary progressive multiple sclerosis

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - interferon alfa-2a 6 miu/ml;   - solution for injection - 3miu/0.5ml - active: interferon alfa-2a 6 miu/ml   excipient: ammonium acetate benzyl alcohol glacial acetic acid polysorbate 80 sodium chloride sodium hydroxide water for injection - roferon-a is indicated for the treatment of basal cell carcinoma, carcinoid syndrome, chronic lymphocytic leukaemia (early stage), chronic myelogenous leukaemia, , condylomata acuminata, cutaneous t cell lymphoma (mycosis fungoides and sezary syndrome), essential thrombocythaemia, hairy cell leukaemia, kaposi's sarcoma associated with aids, malignant melanoma, multiple myeloma, non-hodgkin's lymphoma (low and intermediate grade), renal cell carcinoma (recurrent or metastatic).

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - interferon alfa-2a 12 miu/ml;   - solution for injection - 6miu/0.5ml - active: interferon alfa-2a 12 miu/ml   excipient: ammonium acetate benzyl alcohol glacial acetic acid polysorbate 80 sodium chloride sodium hydroxide water for injection - roferon-a is indicated for the treatment of basal cell carcinoma, carcinoid syndrome, chronic lymphocytic leukaemia (early stage), chronic myelogenous leukaemia, , condylomata acuminata, cutaneous t cell lymphoma (mycosis fungoides and sezary syndrome), essential thrombocythaemia, hairy cell leukaemia, kaposi's sarcoma associated with aids, malignant melanoma, multiple myeloma, non-hodgkin's lymphoma (low and intermediate grade), renal cell carcinoma (recurrent or metastatic).

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - interferon alfa-2a 18 miu/ml;   - solution for injection - 9miu/0.5ml - active: interferon alfa-2a 18 miu/ml   excipient: ammonium acetate benzyl alcohol glacial acetic acid polysorbate 80 sodium chloride sodium hydroxide water for injection - roferon-a is indicated for the treatment of basal cell carcinoma, carcinoid syndrome, chronic lymphocytic leukaemia (early stage), chronic myelogenous leukaemia, , condylomata acuminata, cutaneous t cell lymphoma (mycosis fungoides and sezary syndrome), essential thrombocythaemia, hairy cell leukaemia, kaposi's sarcoma associated with aids, malignant melanoma, multiple myeloma, non-hodgkin's lymphoma (low and intermediate grade), renal cell carcinoma (recurrent or metastatic).

European Union - English - EMA (European Medicines Agency)

bayer ag  - interferon beta-1b - multiple sclerosis - immunostimulants, - betaferon is indicated for the treatment ofpatients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis;patients with relapsing-remitting multiple sclerosis and two or more relapses within the last two years;patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses.

European Union - English - EMA (European Medicines Agency)

merck sharp dohme ltd  - peginterferon alfa-2b - hepatitis c, chronic - immunostimulants, - adults (tritherapy)viraferonpeg in combination with ribavirin and boceprevir (tritherapy) is indicated for the treatment of chronic-hepatitis-c (chc) genotype-1 infection in adult patients (18 years of age and older) with compensated liver disease who are previously untreated or who have failed previous therapy.please refer to the ribavirin and boceprevir summaries of product characteristics (smpcs) when viraferonpeg is to be used in combination with these medicines.adults (bitherapy and monotherapy)viraferonpeg is indicated for the treatment of adult patients (18 years of age and older) with chc who are positive for hepatitis-c-virus rna (hcv-rna), including patients with compensated cirrhosis and / or co-infected with clinically stable hiv.viraferonpeg in combination with ribavirin (bitherapy) is indicated for the treatment of chc infection in adult patients who are previously untreated including patients with clinically stable hiv co-infection and in adult patients who have failed previous treatment with interferon alpha (pegylated or non-pegylated) and ribavirin combination therapy or interferon alpha monotherapy.interferon monotherapy, including viraferonpeg, is indicated mainly in case of intolerance or contraindication to ribavirin.please refer to the ribavirin smpc when viraferonpeg is to be used in combination with ribavirin.paediatric population (bitherapy)viraferonpeg is indicated in a combination regimen with ribavirin for the treatment of children three years of age and older and adolescents, who have chronic hepatitis c, previously untreated, without liver decompensation, and who are positive for hcv-rna.when deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that may be irreversible in some patients. the decision to treat should be made on a case-by-case basis.please refer to the ribavirin smpc for capsules or oral solution when viraferonpeg is to be used in combination with ribavirin.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - interferon beta-1b, quantity: 0.25 mg/ml - injection, powder for - excipient ingredients: albumin; mannitol - betaferon is indicated for the treatment of: - ambulatory patients with relapsing-remitting multiple sclerosis (ms) characterised by at least two attacks of neurologic dysfunction over a two year period followed by complete or incomplete recovery. - betaferon is also indicated for the reduction of frequency and severity of clinical relapses, and for the slowing of progression of disease in patients with secondary progressive multiple sclerosis. - the treatment of patients with a single clinical event suggestive of multiple sclerosis and at least two clinically silent magnetic resonance imaging (mri) lesions characteristic of multiple sclerosis, if alternative diagnoses have been excluded.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - interferon alfa-2a -

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - interferon alfa-2a -